207 related articles for article (PubMed ID: 15517009)
1. Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis.
Jantunen E; Nihtinen A; Volin L; Juvonen E; Parkkali T; Ruutu T; Anttila VJ
Bone Marrow Transplant; 2004 Nov; 34(10):891-5. PubMed ID: 15517009
[TBL] [Abstract][Full Text] [Related]
2. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001).
Safdar A; Singhal S; Mehta J
Cancer; 2004 Jun; 100(11):2456-61. PubMed ID: 15160352
[TBL] [Abstract][Full Text] [Related]
5. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years.
Hovi L; Saarinen-Pihkala UM; Vettenranta K; Saxen H
Bone Marrow Transplant; 2000 Nov; 26(9):999-1004. PubMed ID: 11100280
[TBL] [Abstract][Full Text] [Related]
6. Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
Trenschel R; Peceny R; Runde V; Elmaagacli A; Dermoumi H; Heintschel von Heinegg E; Müller KD; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2000 Nov; 26(9):993-7. PubMed ID: 11100279
[TBL] [Abstract][Full Text] [Related]
7. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit.
Bassetti M; Ansaldi F; Nicolini L; Malfatto E; Molinari MP; Mussap M; Rebesco B; Bobbio Pallavicini F; Icardi G; Viscoli C
J Antimicrob Chemother; 2009 Sep; 64(3):625-9. PubMed ID: 19622536
[TBL] [Abstract][Full Text] [Related]
8. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients.
Jantunen E; Ruutu P; Niskanen L; Volin L; Parkkali T; Koukila-Kähkölä P; Ruutu T
Bone Marrow Transplant; 1997 Apr; 19(8):801-8. PubMed ID: 9134172
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and outcome for nosocomial breakthrough candidaemia.
Pasqualotto AC; Nedel WL; Machado TS; Severo LC
J Infect; 2006 Mar; 52(3):216-22. PubMed ID: 15936825
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic SCT in patients with a history of invasive fungal infection.
Zhang P; Song A; Wang Z; Feng S; Qiu L; Han M
Bone Marrow Transplant; 2009 Apr; 43(7):533-7. PubMed ID: 19104496
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention.
Safdar A; Rodriguez GH; Mihu CN; Mora-Ramos L; Mulanovich V; Chemaly RF; Champlin RE; Khouri I
Bone Marrow Transplant; 2010 Feb; 45(2):339-47. PubMed ID: 19561648
[TBL] [Abstract][Full Text] [Related]
14. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
Sarina B; Mariotti J; Bramanti S; Morabito L; Crocchiolo R; Rimondo A; Tordato F; Pocaterra D; Casari E; De Philippis C; Carlo-Stella C; Santoro A; Castagna L
Transpl Infect Dis; 2018 Aug; 20(4):e12906. PubMed ID: 29668124
[TBL] [Abstract][Full Text] [Related]
15. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients.
Jantunen E; Salonen J; Juvonen E; Koivunen E; Siitonen T; Lehtinen T; Kuittinen O; Leppä S; Anttila VJ; Itälä M; Wiklund T; Remes K; Nousiainen T
Eur J Haematol; 2004 Sep; 73(3):174-8. PubMed ID: 15287914
[TBL] [Abstract][Full Text] [Related]
16. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
17. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation.
Dvorak CC; Steinbach WJ; Brown JM; Agarwal R
Bone Marrow Transplant; 2005 Oct; 36(7):621-9. PubMed ID: 16044133
[TBL] [Abstract][Full Text] [Related]
18. Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients.
Plantinga TS; van der Velden WJ; Ferwerda B; van Spriel AB; Adema G; Feuth T; Donnelly JP; Brown GD; Kullberg BJ; Blijlevens NM; Netea MG
Clin Infect Dis; 2009 Sep; 49(5):724-32. PubMed ID: 19614557
[TBL] [Abstract][Full Text] [Related]
19. [Invasive fungal infections in liver transplant recipients: analysis of 21 cases].
Miguélez M; Lumbreras C; Herrero JA; Aguado JM; del Palacio A; Colina F; Gómez R; Lizasoain M; Moreno E; Rodríguez-Noriega A
Med Clin (Barc); 1998 Mar; 110(11):406-10. PubMed ID: 9608495
[TBL] [Abstract][Full Text] [Related]
20. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
